Cowen & Co. analyst Ronald Josey maintains Amazon.com (NASDAQ:AMZN) with a Outperform and lowers the price target from $160 to $140.
The Most Important Catalyst For Merck’s Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients.
